Ben Kleinstiver is a biochemist and genome editor with interests in protein engineering and genome editing technology development, and a long-term goal of translating these technologies into molecular medicines. He received his Ph.D in Biochemistry from the University of Western Ontario, and completed his postdoctoral studies at Massachusetts General Hospital and Harvard Medical School. Within the Center for Genomic Medicine at MGH, the Kleinstiver laboratory develops scalable methods for molecular engineering to accelerate the development of CRISPR technologies. The major goals of the research in his laboratory are to address limitations of existing technologies, to develop new capabilities that will help solve important research questions at the forefront of the genome editing field, all with the hope of providing safe and effective treatments for patients.